Vivoryon: Develops small molecule medicines that modulate the activity and stability of pathologically altered proteins. Lead candidate varoglutamstat, currently in VIVIAD EU Ph2b and VIVA-MIND US Ph2a/2b studies in Alzheimer’s disease (AD), targets all three major hallmarks of AD (Abeta pathology, tau pathology, neuroinflammation) upstream of other approaches. Varoglutamstat Ph2a trial showed significant improvement in cognition parameter within 3 months and Lilly’s mAb donanemab Ph2 data provided further validation of the N3pE amyloid target.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Central Nervous System
Europe, Public
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
Weinbergweg 22
Halle/Saale, 06120

Company Participants at Vivoryon KOL Breakfast and Networking Event at AAIC 2022

  • Ulrich Dauer, CEO

Top 10 Holders of Vivoryon Therapeutics N.V.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
GS&P Kapitalanlagegesellschaft SA 5.52 1,330,000 0.00 Stakes 5/26/23
Mackenzie Financial Corp. 4.37 1,053,206 0.00 Stakes 12/31/22
Mackenzie Investments Asia Ltd. 3.62 797,264 0.00 Funds 9/30/22
Lupus alpha Asset Management AG 3.39 817,500 0.00 Stakes 5/26/23
Norges Bank Investment Management 1.73 415,999 0.00 Funds 12/31/22
Mackenzie Investments Europe Ltd. 1.24 274,132 0.00 Funds 9/30/22
Matejka & Partner Asset Management GmbH 1.05 253,760 0.00 Funds 5/23/23
Kairos Partners SGR SpA 0.83 200,000 0.00 Funds 2/28/23
Lemanik SA 0.74 178,412 0.00 Funds 4/28/23
GVC Gaesco Gestión SGIIC SA 0.25 54,999 0.00 Funds 9/30/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.